Company Profiles

driven by the PitchBook Platform

Gemmus Pharma

Gemmus Pharma
2007 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE
$1.2M LATEST DEAL AMOUNT
$7.98M TOTAL AMOUNT RAISED
Description

Developer of therapeutics for the treatment of influenza and other infectious diseases. The company develops GP1681, a non-peptidic eiconsanoid analog that is used for the treatment of influenza infections that require hospitalization as either a stand-alone treatment or co-therapy with an antiviral drug, as oseltamivir. It is also developing EP2 and EP4 agonists for the treatment of influenza.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
409 Illinois Avenue
San Francisco, CA 94158
United States

+1 (415) 978-2151
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Gemmus Pharma’s full profile, request a free trial.

Gemmus Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Angel (individual) 01-Dec-2014 $1.2M $7.98M Completed Startup
3. Later Stage VC (Series B) 13-May-2014 00.000 00.000 000.00 Completed Generating Revenue
2. Angel (individual) 01-Oct-2013 $2M $3.46M Completed Generating Revenue
1. Early Stage VC (Series A) 28-Jun-2012 $1.46M $1.46M $7.31M Completed Product Development
To view this company’s complete deal history including valuation and funding request access »

Gemmus Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series A 5,724,370 $0.001000 $0.02 $0.26 $0.26 1x $0.26 16.36%
To view this company’s complete Cap Table request access »

Gemmus Pharma Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BlueTree Allied Angels Venture Capital Minority 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator Minority 000 0000 000000 0
Individual Investor Angel (individual) Minority 000 0000 000000 0
Life Science Angels Angel Group Minority 000 0000 000000 0
Tech Coast Angels Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Gemmus Pharma Executive Team (4)

Name Title Board
Seat
Contact
Info
Daryl Faulds Ph.D Chief Executive Officer & Board Member
William Guilford Ph.D President, Board Member & Co-Founder
Jonathan Ross Chief Financial Officer
William Holstein Senior Vice President, Business Development

Gemmus Pharma Board Members (4)

Name Representing Role Since Contact
Info
Christopher Dunn MD Self Board Member 000 0000
Daryl Faulds Ph.D Gemmus Pharma Chief Executive Officer & Board Member 000 0000
Larry Miller Self Board Member 000 0000
Marc Rubin MD Self Board Member 000 0000